Starting Oct. 1, 2025, a new diagnosis code was added to the detailed list of codes used by health care providers: the remission of type 2 diabetes.

Use lifestyle interventions to show no signs of type 2 diabetes for at least three months? There's a code for that: E11.A.

Introduces New Model That Delivers Greater Coding Precision and Automation to Reduce Errors, Accelerate Payments, and Close the Loop Between Care ...

In a study from Korea, adults with type 2 diabetes had a lower risk for autoimmune rheumatic diseases after starting an SGLT2 ...

Non-functional adrenal tumors were associated with an increased risk for psychiatric and sleep disorders, especially for younger patients.

A real-world analysis has confirmed the negative impact on patients when they lose copay assistance for treatments for retina and macular disease. Presented today during a session at the annual ...

Electronic health record (EHR) adoption was driven, in part, by a recognition of the power of data. Given the complexities of healthcare ...

The aggregation of healthcare data is hampered by issues such as fragmented systems, lack of data quality, and integration ...

Scientists at CSIRO, Australia's national science agency, have identified simpler and less invasive methods to improve ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adults.

Emerging clinical evidence supporting an immunomodulatory effect The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in clinical practice has increased as the multisystem benefits of this ...

Type 1 diabetes was linked to increased risk for dementia, especially vascular dementia, non-Alzheimer-nonvascular dementia, and Alzheimer disease.